LETROZOLE 2.5mg. IP

An aromatase inhibitor that induces ovulation in patients with irregular periods and treats postmenopausal women with breast cancer. Blocks the amount of estrogen produced by the body. (Christopher Dunn, 2006) A well-tolerated and effective drug in metastatic breast cancer in postmenopausal women. (Silvia Dellapasqua, 2010) Inhibits tumor proliferation to a greater extent than tamoxifen. (Matthew J Ellis, 2003) Possesses greater potency than other aromatase inhibitors, including anastrozole, exemestane, formestane, and aminoglutethimide. (Bhatnagar, 2007) A clinically beneficial and cost-effective treatment option as compared to tamoxifen in first-line therapy for advanced breast cancer. (Ichiro Okubo, 2005) A viable alternative to tamoxifen for the treatment of advanced, metastatic breast cancer, as well as in the neoadjuvant and extended adjuvant settings. (Monnier, 2006) An effective ovulation-inducing agent in women with clomiphene resistance or failure. (George, 2011) Shows a higher pregnancy rate than clomiphene citrate in polycystic ovaries patients. (V Atay, 2006) The first-line treatment for anovulatory patients with polycystic ovaries. (V Atay, 2006) Exhibits a superior efficacy as compared to clomiphene citrate in patients with unexplained infertility undergoing superovulation and intrauterine insemination. (Usama M Fouda, 2011)